James Waldron

After seeing success with the acquisition of Yellow Jersey Therapeutics by Johnson & Johnson this year, Kaken Pharmaceutical and Numab Therapeutics have signed another inflammation-focused collaboration.

A spin-out from the University of Edinburgh in Scotland is already equipped with 15 million pounds ($19 million) in seed funding as the newly unveiled biotech continues its mission to find one-time cancer treatments.

“They need to find a bigger venue,” an attendee mutters as they pull their coat tight and brave the British rain to find one of the myriad overflow venues for the Jefferies London Healthcare Conference 2024.

Pfizer and Flagship Pioneering are continuing to fill in the blanks for their 10-program partnership, unveiling agreements with two more Flagship-founded biotechs to chase targets in obesity and lung cancer.

With President-elect Trump's incoming administration having suggested it could create a national bitcoin reserve, a selection of biotechs have this

Novartis has slimmed down its clinical-stage programs by nearly 40% in recent years as the Big Pharma “took to heart” data showing it wasn't getting good value from its medicines, CEO Vas Narasimhan, M.D., told investors.

Novartis had one eye on the struggles its peers have encountered in the muscular dystrophy space when it decided to acquire Kate Therapeutics, according to the Big Pharma's CEO.

LONDON—It's been a big year for Genmab. While celebrating its 25th anniversary, the cancer-focused biopharma hasn't rested on its laurels—securing

Japan-based Kyowa Kirin is fronting $330 million and pledging up to $1.1 billion in milestones to split the U.S. profits of Kura Oncology's phase

AstraZeneca has ended work on an opioid use disorder (OUD) drug after the orexin 1 receptor antagonist demonstrated a drug-drug interaction with an antifungal during a phase 2 trial.